The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals

Authors:
George Zogopoulos McGill University Health Centre, Montreal, Quebec, Canada

Search for other papers by George Zogopoulos in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Ido Haimi New York University Langone Health, New York, NY

Search for other papers by Ido Haimi in
Current site
Google Scholar
PubMed Close
 MD
,
Shenin A. Sanoba New York University Langone Health, New York, NY

Search for other papers by Shenin A. Sanoba in
Current site
Google Scholar
PubMed Close
 MS, CGC
,
Jessica N. Everett New York University Langone Health, New York, NY

Search for other papers by Jessica N. Everett in
Current site
Google Scholar
PubMed Close
 MS, CGC
,
Yifan Wang McGill University Health Centre, Montreal, Quebec, Canada

Search for other papers by Yifan Wang in
Current site
Google Scholar
PubMed Close
 MD
,
Bryson W. Katona University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

Search for other papers by Bryson W. Katona in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
James J. Farrell Yale School of Medicine, Yale University, New Haven, CT

Search for other papers by James J. Farrell in
Current site
Google Scholar
PubMed Close
 MD, MBChB
,
Aaron J. Grossberg Oregon Health & Science University, Portland, OR

Search for other papers by Aaron J. Grossberg in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Salvatore Paiella General and Pancreatic Surgery Unit, Pancreas Institute, University of Verona, Verona, Italy

Search for other papers by Salvatore Paiella in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Kelsey A. Klute University of Nebraska Medical Center, Omaha, NE

Search for other papers by Kelsey A. Klute in
Current site
Google Scholar
PubMed Close
 MD
,
Yan Bi Mayo Clinic, Jacksonville, FL

Search for other papers by Yan Bi in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Michael B. Wallace Mayo Clinic, Jacksonville, FL

Search for other papers by Michael B. Wallace in
Current site
Google Scholar
PubMed Close
 MD, MPH
,
Richard S. Kwon Michigan Medicine, Ann Arbor, MI

Search for other papers by Richard S. Kwon in
Current site
Google Scholar
PubMed Close
 MD, MS
,
Elena M. Stoffel Michigan Medicine, Ann Arbor, MI

Search for other papers by Elena M. Stoffel in
Current site
Google Scholar
PubMed Close
 MD, MPH
,
Raymond C. Wadlow Inova Schar Cancer Institute, Fairfax, VA

Search for other papers by Raymond C. Wadlow in
Current site
Google Scholar
PubMed Close
 MD
,
Daniel A. Sussman University of Miami Health System, Miami, FL

Search for other papers by Daniel A. Sussman in
Current site
Google Scholar
PubMed Close
 MD, MPH
,
Nipun B. Merchant University of Miami Health System, Miami, FL

Search for other papers by Nipun B. Merchant in
Current site
Google Scholar
PubMed Close
 MD
,
Jennifer B. Permuth Moffitt Cancer Center, Tampa, FL

Search for other papers by Jennifer B. Permuth in
Current site
Google Scholar
PubMed Close
 PhD, MS
,
Talia Golan Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Search for other papers by Talia Golan in
Current site
Google Scholar
PubMed Close
 MD
,
Maria Raitses-Gurevich Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Search for other papers by Maria Raitses-Gurevich in
Current site
Google Scholar
PubMed Close
 PhD
,
Andrew M. Lowy UC San Diego Health, La Jolla, CA

Search for other papers by Andrew M. Lowy in
Current site
Google Scholar
PubMed Close
 MD
,
Joy Liau UC San Diego Health, La Jolla, CA

Search for other papers by Joy Liau in
Current site
Google Scholar
PubMed Close
 MD
,
Joanne M. Jeter Huntsman Cancer Institute, Salt Lake City, UT

Search for other papers by Joanne M. Jeter in
Current site
Google Scholar
PubMed Close
 MD, MS
,
James M. Lindberg UMass Memorial Health, Worcester, MA

Search for other papers by James M. Lindberg in
Current site
Google Scholar
PubMed Close
 MD
,
Daniel C. Chung Massachusetts General Hospital and Harvard Medical School, Boston, MA

Search for other papers by Daniel C. Chung in
Current site
Google Scholar
PubMed Close
 MD
,
Julie Earl Ramón y Cajal Health Research Institute, Madrid, Spain

Search for other papers by Julie Earl in
Current site
Google Scholar
PubMed Close
 PhD, MS
,
Teresa A. Brentnall University of Washington Medical Center, Seattle, WA

Search for other papers by Teresa A. Brentnall in
Current site
Google Scholar
PubMed Close
 MD
,
Kasmintan A. Schrader BC Cancer, Vancouver, British Columbia, Canada

Search for other papers by Kasmintan A. Schrader in
Current site
Google Scholar
PubMed Close
 PhD, MBBS
,
Vivek Kaul University of Rochester Medical Center, Rochester, NY

Search for other papers by Vivek Kaul in
Current site
Google Scholar
PubMed Close
 MD
,
Chenchan Huang New York University Langone Health, New York, NY

Search for other papers by Chenchan Huang in
Current site
Google Scholar
PubMed Close
 MD
,
Hersh Chandarana New York University Langone Health, New York, NY

Search for other papers by Hersh Chandarana in
Current site
Google Scholar
PubMed Close
 MD
,
Caroline Smerdon Arbor Research Collaborative for Health, Ann Arbor, MI

Search for other papers by Caroline Smerdon in
Current site
Google Scholar
PubMed Close
 MPH
,
John J. Graff Arbor Research Collaborative for Health, Ann Arbor, MI

Search for other papers by John J. Graff in
Current site
Google Scholar
PubMed Close
 PhD, MS
,
Fay Kastrinos Columbia University Irving Medical Center/Herbert Irving Comprehensive Cancer Center, New York, NY

Search for other papers by Fay Kastrinos in
Current site
Google Scholar
PubMed Close
 MD
,
Sonia S. Kupfer University of Chicago, Chicago, IL

Search for other papers by Sonia S. Kupfer in
Current site
Google Scholar
PubMed Close
 MD
,
Aimee L. Lucas Icahn School of Medicine at Mount Sinai, New York, NY

Search for other papers by Aimee L. Lucas in
Current site
Google Scholar
PubMed Close
 MD, MS
,
Rosalie C. Sears Oregon Health & Science University, Portland, OR

Search for other papers by Rosalie C. Sears in
Current site
Google Scholar
PubMed Close
 PhD
,
Randall E. Brand University of Pittsburgh, Pittsburgh, PA

Search for other papers by Randall E. Brand in
Current site
Google Scholar
PubMed Close
 MD
,
Giovanni Parmigiani Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA

Search for other papers by Giovanni Parmigiani in
Current site
Google Scholar
PubMed Close
 PhD
,
Diane M. Simeone New York University Langone Health, New York, NY

Search for other papers by Diane M. Simeone in
Current site
Google Scholar
PubMed Close
 MD
, and
on behalf of the PRECEDE Consortium
Search for other papers by on behalf of the PRECEDE Consortium in
Current site
Google Scholar
PubMed Close
Volume/Issue:
Volume 22: Issue 3
Online Publication Date:
06 Apr 2024
DOI:
https://doi.org/10.6004/jnccn.2023.7097
Restricted access

Background: Pancreatic adenocarcinoma (PC) is a highly lethal malignancy with a survival rate of only 12%. Surveillance is recommended for high-risk individuals (HRIs), but it is not widely adopted. To address this unmet clinical need and drive early diagnosis research, we established the Pancreatic Cancer Early Detection (PRECEDE) Consortium. Methods: PRECEDE is a multi-institutional international collaboration that has undertaken an observational prospective cohort study. Individuals (aged 18–90 years) are enrolled into 1 of 7 cohorts based on family history and pathogenic germline variant (PGV) status. From April 1, 2020, to November 21, 2022, a total of 3,402 participants were enrolled in 1 of 7 study cohorts, with 1,759 (51.7%) meeting criteria for the highest-risk cohort (Cohort 1). Cohort 1 HRIs underwent germline testing and pancreas imaging by MRI/MR-cholangiopancreatography or endoscopic ultrasound. Results: A total of 1,400 participants in Cohort 1 (79.6%) had completed baseline imaging and were subclassified into 3 groups based on familial PC (FPC; n=670), a PGV and FPC (PGV+/FPC+; n=115), and a PGV with a pedigree that does not meet FPC criteria (PGV+/FPC–; n=615). One HRI was diagnosed with stage IIB PC on study entry, and 35.1% of HRIs harbored pancreatic cysts. Increasing age (odds ratio, 1.05; P<.001) and FPC group assignment (odds ratio, 1.57; P<.001; relative to PGV+/FPC–) were independent predictors of harboring a pancreatic cyst. Conclusions: PRECEDE provides infrastructure support to increase access to clinical surveillance for HRIs worldwide, while aiming to drive early PC detection advancements through longitudinal standardized clinical data, imaging, and biospecimen captures. Increased cyst prevalence in HRIs with FPC suggests that FPC may infer distinct biological processes. To enable the development of PC surveillance approaches better tailored to risk category, we recommend adoption of subclassification of HRIs into FPC, PGV+/FPC+, and PGV+/FPC– risk groups by surveillance protocols.

Submitted July 25, 2023; final revision received October 9, 2023; accepted for publication October 9, 2023.

A list of the PRECEDE Consortium collaborators is provided in Appendix 1 in the supplementary materials (available online with this article).

Author contributions: Study concept and design: Zogopoulos, Haimi, Simeone. Data acquisition: All authors. Data analysis and interpretation: Zogopoulos, Haimi, Sanoba, Everett, Wang, Parmigiani, Simeone. Funding acquisition: Zogopoulos, Kastrinos, Kupfer, Lucas, Sears, Brand, Parmigiani, Simeone. Administrative, technical, or material support: All authors. Supervision: Zogopoulos, Simeone. Writing—original draft: Zogopoulos, Haimi, Sanoba, Everett, Wang, Parmigiani, Simeone. Writing—review & editing: All authors.

Disclosures: Dr. Zogopoulos has disclosed receiving grant/research support from Immunovia. Dr. Farrell has disclosed serving as a member of the speaker’s bureau for Interpace Diagnostics. Dr. Paiella has disclosed serving as a consultant for Alpha Tau Medical. Dr. Golan has disclosed receiving grant/research support from AstraZeneca and Bristol Myers Squibb; serving as a consultant for AbbVie, AstraZeneca, Teva, and MSD Merck; and serving on a speaker’s bureau for AbbVie and Roche. Dr. Schrader has disclosed serving as a consultant for AstraZeneca Canada, Merck, and Precision Rx-Dx. Dr. Lucas has disclosed participating in research for Immunovia; serving as a scientific advisor for ClearNote Health and Immunovia; and serving as a consultant for Immunovia. Dr. Sears has disclosed serving as a scientific advisor for Rappta Therapeutics and Larkspur Biosciences; and receiving grant/research support from AstraZeneca and Cardiff Oncology. Dr. Brand has disclosed receiving grant/research support from Immunova and Freenome. Dr. Parmigiani has disclosed cofounding Phaeno Biotech; serving as a consultant for Delfi Diagnostics; and serving as a scientific advisor for REALM IDx. Dr. Simeone has disclosed serving as a scientific advisor for ClearNote Health, Interpace, Merck & Co., Bayer, and FibroGen; and receiving grant/research support from Micronoma, Immunovia, ClearNote Health, Biological Dynamics, and Tempus. The remaining authors have disclosed that they have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.

Funding: Research reported in this publication was supported by an anonymous donor through NYU Langone (D.M. Simeone) and Ambry Genetics, TrovaNOW, Amazon Web Services, Project Purple, REALM IDx, and Invicro through the PRECEDE Consortium.

Disclaimer: The funders had no role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication.

Supplementary material: Supplementary material associated with this article is available online at https://doi.org/10.6004/jnccn.2023.7097. The supplementary material has been supplied by the author(s) and appears in its originally submitted form. It has not been edited or vetted by JNCCN. All contents and opinions are solely those of the author. Any comments or questions related to the supplementary materials should be directed to the corresponding author.

Correspondence: George Zogopoulos, MD, PhD, Departments of Surgery and Oncology, McGill University, McGill University Health Centre, 1001 Decarie Boulevard, Room EM2.3210, Montreal, Quebec, H4A 3J1 Canada. Email: george.zogopoulos@mcgill.ca; and
Diane M. Simeone, MD, Department of Surgery and Department of Pathology, Perlmutter Cancer Center, New York University Langone Health, 240 East 38th Street, 20th Floor, New York, NY 10016. Email: diane.simeone@nyulangone.org

Supplementary Materials

    • Supplemental Materials (PDF 3.25 MB)
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Yu J, Yang X, He W, et al. Burden of pancreatic cancer along with attributable risk factors in Europe between 1990 and 2019, and projections until 2039. Int J Cancer 2021;149:993–1001.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Pourshams A, Sepanlou SG, Ikuta KS, et al. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2019;4:934–947.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin 2023;73:17–48.

  • 4.

    Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med 2014;371:1039–1049.

  • 5.

    Blackford AL, Canto MI, Klein AP, et al. Recent trends in the incidence and survival of stage 1A pancreatic cancer: a Surveillance, Epidemiology, and End Results analysis. J Natl Cancer Inst 2020;112:1162–1169.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Owens DK, Davidson KW, Krist AH, et al. Screening for pancreatic cancer: US Preventive Services Task Force reaffirmation recommendation statement. JAMA 2019;322:438–444.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Overbeek KA, Goggins MG, Dbouk M, et al. Timeline of development of pancreatic cancer and implications for successful early detection in high-risk individuals. Gastroenterology 2022;162:772–785.e4.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Wang Y, Cuggia A, Chen YI, et al. Is biannual surveillance for pancreatic cancer sufficient in individuals with genetic syndromes or familial pancreatic cancer? J Natl Compr Canc Netw 2022;20:663–673.e12.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Konings ICAW, Harinck F, Poley JW, et al. Prevalence and progression of pancreatic cystic precursor lesions differ between groups at high risk of developing pancreatic cancer. Pancreas 2017;46:28–34.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Overbeek KA, Levink IJM, Koopmann BDM, et al. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut 2022;71:1152–1160.

  • 11.

    Chhoda A, Vodusek Z, Wattamwar K, et al. Late-stage pancreatic cancer detected during high-risk individual surveillance: a systematic review and meta-analysis. Gastroenterology 2022;162:786–798.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Klatte DCF, Boekestijn B, Wasser MN, et al. Pancreatic cancer surveillance in carriers of a germline CDKN2A pathogenic variant: yield and outcomes of a 20-year prospective follow-up. J Clin Oncol 2022;40:3267–3277.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Dbouk M, Katona BW, Brand RE, et al. The multicenter cancer of pancreas screening study: impact on stage and survival. J Clin Oncol 2022;40:3257–3266.

  • 14.

    Klatte DCF, Boekestijn B, Onnekink AM, et al. Surveillance for pancreatic cancer in high-risk individuals leads to improved outcomes: a propensity score-matched analysis. Gastroenterology 2023;164:1223–1231.e4.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Goggins M, Overbeek KA, Brand RE, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 2020;69:7–17.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Aslanian HR, Lee JH, Canto MI. AGA clinical practice update on pancreas cancer screening in high-risk individuals: expert review. Gastroenterology 2020;159:358–362.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Sawhney MS, Calderwood AH, Thosani NC, et al. ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations. Gastrointest Endosc 2022;95:817–826.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Underhill ML, Pozzar R, Chung D, et al. Health care provider perceptions of caring for individuals with inherited pancreatic cancer risk. J Cancer Educ 2020;35:194–203.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Zogopoulos G, Bi Y, Brand RE, et al. The PRECEDE consortium: a longitudinal international cohort study of individuals with genetic risk or familial pancreatic cancer. J Clin Oncol 2022;40(Suppl):Abstract e16239.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Gonda TA, Everett JN, Wallace M, et al. Recommendations for a more organized and effective approach to the early detection of pancreatic cancer from the PRECEDE (Pancreatic Cancer Early Detection) Consortium. Gastroenterology 2021;161:1751–1757.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Gonda TA, Farrell J, Wallace M, et al. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detection Consortium. Gastrointest Endosc 2022;95:723–732.e7.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Huang C, Simeone DM, Luk L, et al. Standardization of MRI screening and reporting in individuals with elevated risk of pancreatic ductal adenocarcinoma: consensus statement of the PRECEDE Consortium. AJR Am J Roentgenol 2022;219:903–914.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Abe T, Blackford AL, Tamura K, et al. Deleterious germline mutations are a risk factor for neoplastic progression among high-risk individuals undergoing pancreatic surveillance. J Clin Oncol 2019;37:1070–1080.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000;119:1447–1453.

  • 25.

    Dbouk M, Brewer Gutierrez OI, Lennon AM, et al. Guidelines on management of pancreatic cysts detected in high-risk individuals: an evaluation of the 2017 Fukuoka guidelines and the 2020 International Cancer of the Pancreas Screening (CAPS) Consortium statements. Pancreatology 2021;21:613–621.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Notta F, Chan-Seng-Yue M, Lemire M, et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature 2016;538:378–382.

  • 27.

    Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114–1117.

  • 28.

    Omori Y, Ono Y, Morikawa T, et al. Serine/threonine kinase 11 plays a canonical role in malignant progression of KRAS -mutant and GNAS -wild-type intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 2023;277:e384–395.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Sato N, Rosty C, Jansen M, et al. STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol 2001;159:2017–2022.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Tanaka M, Fernández-del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 2017;17:738–753.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Paniccia A, Polanco PM, Boone BA, et al. Prospective, multi-institutional, real-time next-generation sequencing of pancreatic cyst fluid reveals diverse genomic alterations that improve the clinical management of pancreatic cysts. Gastroenterology 2023;164:117–133.e7.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Canto MI, Almario JA, Schulick RD, et al. Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance. Gastroenterology 2018;155:740–751.e2.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Katona BW, Klute K, Brand RE, et al. Racial, ethnic, and sex-based disparities among high-risk individuals undergoing pancreatic cancer surveillance. Cancer Prev Res (Phila) 2023;16:343–352.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Simons RL, Lei MK, Beach SR, et al. Discrimination, segregation, and chronic inflammation: testing the weathering explanation for the poor health of Black Americans. Dev Psychol 2018;54:1993–2006.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Williams DR, Lawrence JA, Davis BA, et al. Understanding how discrimination can affect health. Health Serv Res 2019;54(Suppl 2):1374–1388.

Copyright:
Copyright © 2024 by the National Comprehensive Cancer Network 2024
Page Numbers:
9
Article Category:
Research Article
Received:
25 Jul 2023
Accepted:
09 Oct 2023
Print Publication Date:
06 Apr 2024
Online Publication Date:
06 Apr 2024

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 9019 5665 424
PDF Downloads 5775 3208 163
EPUB Downloads 0 0 0